Literature DB >> 716925

Crossed immunoelectrophoresis and electroimmunoassay of human IgG subclasses.

V A Oxelius.   

Abstract

Human IgGl, IgG2, IgG3 and IgG4 in WHO pool 67/97, a normal serum pool, Cohn Fraction II and individual sera were examined by crossed immunoelectrophoresis and electroimmunoassay in agarose with IgG subclass specific rabbit antisera. In these methods the fact that IgG subclasses differ in the electrophoretic field is utilized: IgG4 is located anodically, IgG3 cathodically, and IgG2 and IgG1 both anodically and cathodically. The mean, S.D. and range of serum IgG1, IgG2, IgG3 and IgG4 in 20 normal adults found by the electroimmunoassay were given and related to the amount in the WHO pool 67/97. The IgG subclasses values obtained by electroimmunoassay agreed with the values obtained by single radial diffusion. The reproducibility of double determinations (interplate variations) was 1.5--5.5 per cent. Repeated freezing, thawing and storage of the serum at room temperature did not influence quantitation of IgG subclasses. Cohn Fraction II was found to contain smaller amounts of IgG1, IgG2, and IgG4 than those found in the normal serum pools. Crossed immunoelectrophoresis and electroimmunoassay also easily reveal failing quality of IgG subclass antisera. To obtain good antisera in rabbits against IgG subclasses immunization should be done with several myeloma proteins with different electrophoretic mobility within the same subclass.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 716925     DOI: 10.1111/j.1699-0463.1978.tb02567.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Scand C        ISSN: 0304-1328


  10 in total

1.  Imbalanced serum IgG subclass pattern in toxic shock syndrome patients: deficiency of specific IgG1 and IgG4 subclass antibodies to toxic shock syndrome toxin 1.

Authors:  B Christensson; P J Johansson; V A Oxelius
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

2.  Analysis of immunoglobulin isotype levels in acute pneumococcal bacteremia and in convalescence.

Authors:  K Ekdahl; J Rollof; V A Oxelius; J Engellau; J H Braconier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-05       Impact factor: 3.267

3.  Demonstration of a new type of immunoglobulin G receptor in Streptococcus zooepidemicus strains.

Authors:  E B Myhre; G Kronvall
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

4.  IgG sub-class levels in healthy Irish adults--a population study.

Authors:  D J Reen; M B Murphy; A O'Connor; M X FitzGerald
Journal:  Ir J Med Sci       Date:  1981-09       Impact factor: 1.568

5.  Serum IgG subclass antibodies to gliadin and other dietary antigens in children with coeliac disease.

Authors:  S Husby; N Foged; V A Oxelius; S E Svehag
Journal:  Clin Exp Immunol       Date:  1986-06       Impact factor: 4.330

6.  Human immunoglobulin class and subclass specificity of Fc receptors induced by herpes simplex virus type 1.

Authors:  P J Johansson; T Hallberg; V A Oxelius; A Grubb; J Blomberg
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

7.  Humoral immunity in nasal mucosa of patients with common variable immunodeficiency.

Authors:  G Karlsson; P Brandtzaeg; G Hansson; B Petruson; J Björkander; L A Hanson
Journal:  J Clin Immunol       Date:  1987-01       Impact factor: 8.317

8.  The clinical condition of IgA-deficient patients is related to the proportion of IgD- and IgM-producing cells in their nasal mucosa.

Authors:  P Brandtzaeg; G Karlsson; G Hansson; B Petruson; J Björkander; L A Hanson
Journal:  Clin Exp Immunol       Date:  1987-03       Impact factor: 4.330

9.  Quantitative and qualitative investigations of serum IgG subclasses in immunodeficiency diseases.

Authors:  V A Oxelius
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

10.  Immunoglobulin deficiencies in treated patients suffering from rheumatoid arthritis.

Authors:  Sara Kaestner; Hans-Juergen Wolff; Rolf Braeuer; Peter Kaestner
Journal:  Rheumatol Int       Date:  2021-04-29       Impact factor: 2.631

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.